MNOV MediciNova Inc.

8.37
+0.22  (+3%)
Previous Close 8.15
Open 8.24
Price To Book 4.95
Market Cap 361,993,695
Shares 43,248,948
Volume 62,524
Short Ratio
Av. Daily Volume 116,055

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned.
MN-166
Progressive multiple sclerosis (progressive MS)
Phase 2 abstract presented at EASL April 13, 2018. Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint of cholesterol efflux capacity not released).
MN-001
NASH (nonalcoholic steatohepatitis)
Phase 2 data released March 29, 2018 - primary endpoint not met.
MN-166
Methamphetamine dependence
Phase 2b/3 trial launched - June 5, 2019. Enrolment to commence soon.
MN-166
Amyotrophic lateral sclerosis (ALS)
Phase 2/3 trial initiation announced August 6, 2018.
MN-166 (ibudilast)
Degenerative cervical myelopathy (DCM)
Phase 2 initiation announced January 8, 2019.
MN-166
Glioblastoma
Phase 2 trial ongoing.
MN-001
Idiopathic pulmonary fibrosis (IPF)

Latest News

  1. MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium…
  2. MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan
  3. MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia
  4. MediciNova Appoints Kazuko Matsuda to its Board of Directors
  5. MNOV: Readying for Phase 3 Trial in Multiple Sclerosis…
  6. What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)?
  7. MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS
  8. MediciNova to Present at the JMP Securities Life Sciences Conference
  9. MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS
  10. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc.
  11. MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  12. MNOV: Plans in Place for Phase 3 Trial in ALS…
  13. If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today
  14. MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom
  15. The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova
  16. MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
  17. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  18. MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
  19. MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS…
  20. MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China